Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2019 February;67(1) > Minerva Cardioangiologica 2019 February;67(1):64-72

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Cardioangiologica 2019 February;67(1):64-72

DOI: 10.23736/S0026-4725.18.04800-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cell therapy and left ventricular restoration for ischemic cardiomyopathy: long-term results of a perspective, randomized study

Guglielmo STEFANELLI 1 , Fabrizio PIRRO 1, Alina OLARU 1, Paolo GIOVANARDI 2, Marco MELI 1, Mauro CONCARI 1, Paolo L. WELTERT 3

1 Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy; 2 Department of Cardiology, University Hospital, Modena, Italy; 3 Department of Cardiac Surgery, European Hospital, Rome, Italy



BACKGROUND: Aim of this study is to verify the potential advantages and benefits of bone-marrow derived autologous stem cells implantation associated to surgical left ventricular restoration (SVR), to report a new modality of cell delivery to myocardium, and to identify possible side effects of this procedure.
METHODS: Between March 2007 and March 2013, 30 patients affected by ischemic dilative cardiomyopathy who received a SVR operation were enrolled in the study. The population was divided in two groups:16 patients were randomly assigned to receive stem cells therapy in addition to SVR (groupA), 14 patients received a placebo (group B). The two groups were homogeneous in respect of age, gender, preoperative NYHA class, mitral incompetence and left ventricular sizes and volumes. The patients were evaluated by echo and pet-scan before surgery and at 6 months follow-up, and by echo at subsequent follow-up.
RESULTS: Overall 30 days-in hospital mortality was 0 for the entire cohort. At last follow-up ejection fraction increased from 25.3% before surgery to 36.3% in group A, and from 31.8% to 45.6% in group B. Reduction of LVEDD was 6% in group A, 9% in group B. ESLVV and EDLVD decreased more significantly in patients receiving stem cells (55% vs. 35%). Late cardiac mortality at 9 years follow-up was similar in the two groups of patients. No early or late adverse reaction nor cases of infections were observed.
CONCLUSIONS: Patients affected by ischemic cardiomyopathy have a favourable outcome after SVR. A higher reduction of LVEDV and LVESV assessed by CT-Scan evaluation in patients receiving cell therapy, when compared to control group, encourages the evolution and refinement of myocardial regenerative therapy added to SVR.


KEY WORDS: Heart failure - Cell- and tissue-based therapy - Cardiomyopathies

inizio pagina